Lower Drug Costs: Extending Inflation Rebates to Commercial Market and Changing Base Year.
This bill expands the drug inflation rebate mechanism to include medications sold on the commercial market, not just those covered by Medicare programs. If drug prices rise faster than inflation, manufacturers must pay penalties, aiming to reduce costs for individuals with private insurance. Crucially, the bill changes the base year for calculating drug price inflation from 2021 back to 2016, significantly increasing the likelihood and size of these rebates.
Key points
Drug manufacturers must pay rebates if prices increase faster than inflation, now covering drugs sold in the private (commercial) market, not just Medicare.
The base year for calculating drug price inflation is shifted from 2021 to 2016, making it easier to trigger rebates and potentially leading to greater price reductions.
The goal is to stabilize and potentially lower prescription drug costs for families and individuals relying on private insurance plans.
Expired
Citizen Poll